Adaptin Bio (APTN) EBITDA (2023 - 2026)

Adaptin Bio's EBITDA history runs 4 years deep, the most recent figure standing at -$1.1 million for Q1 2026.

• In Q1 2026, EBITDA fell 34.53% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$1.4 million (down 14.29% YoY), while the FY2025 annual figure was -$1.1 million, down 65.49% from the prior year.
• EBITDA came in at -$1.1 million for Q1 2026 at Adaptin Bio, down from $3.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $3.0 million in Q4 2025 to a low of -$1.7 million in Q3 2025.
• A 4-year average of -$269288.5 and a median of -$767320.0 in 2024 frame the typical range for EBITDA.
• On a YoY basis, EBITDA climbed as much as 4216.73% in 2024 and fell as far as 2216.71% in 2024.
• Adaptin Bio's EBITDA stood at -$34155.0 in 2023, then jumped by 4216.73% to $1.4 million in 2024, then soared by 110.64% to $3.0 million in 2025, then sank by 138.63% to -$1.1 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$1.1 million, $3.0 million, and -$1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison